Moberg Pharma
Pharmaceutical company developing and commercializing treatments for nail fungus.
MOB | ST
Overview
Corporate Details
- ISIN(s):
- SE0011311596 (+3 more)
- LEI:
- 549300XFXK7DVGDRP410
- Country:
- Sweden
- Address:
- Gustavslundsvagen 42, 167 51 Stockholm
- Website:
- https://www.mobergpharma.com/
- Sector:
- Manufacturing
Description
Moberg Pharma is a pharmaceutical company that develops and commercializes proprietary medical products, focusing on innovative drug delivery of proven compounds. The company's primary asset is MOB-015, a topical formulation for the treatment of onychomycosis (nail fungus). MOB-015 has demonstrated high fungal cure rates in Phase 3 clinical trials and has received market approval in multiple European countries. It is commercialized under the brand name Terclara® in Sweden and Norway, where it has achieved market leadership. Moberg Pharma's business model aims for lower development risk and faster market entry than traditional pharmaceutical development. The company's strategic goal is to establish MOB-015 as the leading global treatment for nail fungus.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2019-12-09 13:49 |
Moberg Pharma uppnår det primära behandlingsmålet i fas 3 studie med MOB-015 fö…
|
Swedish | PDF • 113.6 KB | ||
| 2019-12-09 13:49 |
Moberg Pharma meets primary endpoint for MOB-015 in a Phase 3 study for the tre…
|
English | PDF • 114.6 KB | ||
| 2019-11-29 08:31 |
Reclassification of series B shares in Moberg Pharma AB (publ)
|
English | PDF • 104.6 KB | ||
| 2019-11-29 08:31 |
Omstämpling av B-aktier i Moberg Pharma AB (publ)
|
Swedish | PDF • 100.7 KB | ||
| 2019-11-19 08:00 | Swedish | PDF • 810.0 KB | |||
| 2019-11-19 08:00 | English | PDF • 805.8 KB | |||
| 2019-11-12 08:00 |
Moberg Pharmas delårsrapport för juli - september 2019 presenteras 19 november …
|
Swedish | PDF • 155.9 KB | ||
| 2019-11-12 08:00 |
Moberg Pharma’s Interim report for July - September 2019 to be published on Nov…
|
English | PDF • 156.3 KB | ||
| 2019-10-30 18:30 |
Bulletin from Moberg Pharma’s AGM on October 30th , 2019
|
English | PDF • 155.2 KB | ||
| 2019-10-30 18:30 |
Kommuniké från Moberg Pharmas årsstämma den 30 oktober 2019
|
Swedish | PDF • 172.1 KB | ||
| 2019-10-21 07:00 |
Moberg Pharma och DongKoo ingår avtal för MOB-015 i Sydkorea
|
Swedish | PDF • 173.2 KB | ||
| 2019-10-21 07:00 |
Moberg Pharma and DongKoo sign agreement for MOB-015 in the Republic of Korea
|
English | PDF • 174.5 KB | ||
| 2019-10-18 16:00 |
Changes to Moberg Pharma´s management team
|
English | PDF • 104.4 KB | ||
| 2019-10-18 16:00 |
Förändring i ledningsgruppen i Moberg Pharma
|
Swedish | PDF • 102.9 KB | ||
| 2019-09-30 18:02 |
Moberg Pharma and Taisho sign exclusive license agreement for MOB-015 in Japan
|
English | PDF • 113.4 KB |
Automate Your Workflow. Get a real-time feed of all Moberg Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Moberg Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Moberg Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-11-11 | Mark Beveridge | Other | Buy | 3,000 | 17,730.00 SEK |
| 2021-11-10 | Mark Beveridge | Other | Buy | 3,000 | 17,310.00 SEK |
| 2021-11-09 | Mark Beveridge | Other | Buy | 5,000 | 29,800.00 SEK |
| 2021-02-10 | Cindy Wong | Other | Buy | 5,000 | 31,675.00 SEK |
| 2021-02-09 | Cindy Wong | Other | Buy | 5,000 | 30,800.00 SEK |
Peer Companies
